News stories about Ignyta (NASDAQ:RXDX) have trended somewhat positive recently, Accern reports. The research group identifies negative and positive media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Ignyta earned a media sentiment score of 0.23 on Accern’s scale. Accern also assigned news headlines about the biopharmaceutical company an impact score of 48.1122408131546 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the headlines that may have effected Accern Sentiment Analysis’s scoring:

A number of equities research analysts have recently commented on RXDX shares. ValuEngine raised shares of Ignyta from a “sell” rating to a “hold” rating in a research note on Thursday, June 15th. BidaskClub cut shares of Ignyta from a “buy” rating to a “hold” rating in a research note on Friday, July 28th. Jefferies Group LLC reaffirmed a “buy” rating and set a $27.00 price objective on shares of Ignyta in a research note on Thursday, June 22nd. Cantor Fitzgerald set a $15.00 price objective on shares of Ignyta and gave the stock a “buy” rating in a research note on Monday, July 10th. Finally, Zacks Investment Research upgraded Ignyta from a “sell” rating to a “hold” rating in a research report on Tuesday, August 15th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. Ignyta has a consensus rating of “Hold” and an average price target of $17.33.

Shares of Ignyta (RXDX) traded up 0.54% on Friday, reaching $9.30. The company’s stock had a trading volume of 32,308 shares. The stock’s market capitalization is $523.15 million. Ignyta has a 1-year low of $4.15 and a 1-year high of $11.45. The company has a 50 day moving average of $9.61 and a 200 day moving average of $8.65.

Ignyta (NASDAQ:RXDX) last issued its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.56) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.63) by $0.07. Equities research analysts expect that Ignyta will post ($2.57) earnings per share for the current fiscal year.

COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Ignyta (RXDX) Stock Price” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another site, it was copied illegally and republished in violation of United States & international copyright law. The original version of this news story can be viewed at

Ignyta Company Profile

Ignyta, Inc is a biotechnology company. The Company is focused on precision medicine in oncology. The Company is pursuing an integrated therapeutic (Rx) and companion diagnostic (Dx) strategy for treating cancer patients. The Company’s pipeline includes various compounds, such as entrectinib, RXDX-105, taladegib and RXDX-106.

Insider Buying and Selling by Quarter for Ignyta (NASDAQ:RXDX)

Receive News & Stock Ratings for Ignyta Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ignyta Inc. and related stocks with our FREE daily email newsletter.